ArrowMark Partners
ArrowMark Partners is an SEC-registered investment adviser based in Denver, Colorado. Their investment objective is clear: deliver
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed ArrowMark Partners Information
Geographic Data
Address: 100 Fillmore Street
City: Denver
State: CO
Zip: 80206
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
ArrowMark Partners is an SEC-registered investment adviser based in Denver, Colorado. Their investment objective is clear: deliver consistent, asymmetric, non-correlated, risk-adjusted returns by applying fundamental research across the capital structure. They focus on compounding wealth by delivering unique, client-driven and absolute return solutions.
Contact Phone:
+13033982929
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 7/2018 | Convene | Series D | 0 |
| 5/2016 | Convene | Series B | 0 |
| 12/2019 | ArcherDX | Series C | 0 |
| 5/2017 | Convene | Series C | 0 |
| 9/2020 | Xometry | Series E | 75M |
| 4/2012 | Sapphire Energy | Series C | 0 |
| 9/2021 | SmartLabs | Series B | 0 |
| 12/2019 | SmartLabs | Series A | 0 |
| 10/2020 | Shift | Post-IPO Equity | 185M |
| 6/2021 | Tvardi Therapeutics | Series B | 0 |
| 6/2018 | Precision BioSciences | Series B | 0 |
| 5/2019 | Inhibrx | Private Placement | 40M |
| 7/2019 | Frontier Medicines | Series B | 88.5M |
| 5/2021 | Binx Health | Series E | 0 |
| 1/2020 | Sonendo | Venture Round | 85M |
| 10/2021 | DNA Script | Series C | 0 |
| 3/2022 | Starry | Post-IPO Equity | 130M |
| 2/2018 | Kiniksa Pharmaceuticals | Series C | 200M |
| 1/2018 | Centrexion | Series D | 67M |
| 12/2021 | Freenome | Series D | 300M |
| 1/2022 | Simcha Therapeutics | Series B | 40M |
| 4/2018 | Kodiak Sciences | Convertible Note | 33M |
| 7/2015 | Twilio | Series E | 130M |
| 8/2018 | Evolve | Series D | 0 |
| 5/2020 | Evolve | Series E | 0 |
| 1/2022 | Big Health | Series C | 0 |
| 5/2015 | MarkLogic | Series F | 102M |
| 4/2019 | SpringWorks Therapeutics | Series B | 125M |
| 6/2018 | Metacrine | Series C | 65M |
| 1/2019 | Beta Bionics | Series B | 63M |
| 7/2019 | Beta Bionics | Series B | 63M |
| 1/2020 | Lyra Therapeutics | Series C | 0 |
| 3/2018 | TCR2 | Series B | 0 |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 8/2022 | Aktis Oncology | Series A | 0 |
| 11/2021 | Fyllo | Series C | 0 |
| 6/2021 | Latch | Post-IPO Equity | 190M |
| 10/2021 | Skyryse | Series B | 0 |
| 6/2016 | Mersana Therapeutics | Series C | 33M |
| 8/2018 | Orchard Therapeutics | Series C | 0 |
| 11/2017 | Intersection | Venture Round | 150M |
| 8/2020 | Taysha Gene Therapies | Series B | 0 |
| 9/2021 | TrialSpark | Series C | 156M |
| 8/2019 | ORIC Pharmaceuticals | Series D | 0 |
| 4/2021 | Adagio Therapeutics | Series C | 0 |
| 11/2018 | NextCure | Series B | 93M |
| 3/2021 | Absci | Venture Round | 0 |
| 2/2018 | Moderna Therapeutics | Series G | 0 |
| 5/2019 | Pulmonx | Series G | 0 |
| 10/2020 | Absci | Series E | 70M |
| 3/2021 | Amunix | Series B | 117M |
| 6/2022 | Dren Bio | Series B | 0 |
| 11/2020 | Adagio Medical | Series E | 0 |
| 7/2021 | Frontier Medicines | Series B | 0 |
| 2/2022 | Beta Bionics | Series C | 0 |
| 12/2017 | Neon Therapeutics | Series B | 36M |
| 7/2018 | Ascentage Pharma | Series C | 150M |
| 11/2021 | Arbor Biotechnologies | Series B | 0 |
| 1/2018 | NexImmune | Series A | 23M |
| 3/2021 | Dataminr | Series F | 0 |
| 9/2018 | Lyra Therapeutics | Series B | 0 |
| 9/2022 | Sonendo | Post-IPO Equity | 63M |
| 6/2020 | 4D Molecular Therapeutics | Series C | 0 |
| 6/2022 | Dren Bio | Series B | 0 |
| 2/2022 | Beta Bionics | Series C | 0 |
| 1/2022 | Simcha Therapeutics | Series B | 0 |
| 1/2022 | Big Health | Series C | 0 |
| 12/2021 | Freenome | Series D | 0 |
| 11/2021 | Arbor Biotechnologies | Series B | 0 |
| 11/2021 | Fyllo | Series C | 0 |
| 10/2021 | Skyryse | Series B | 0 |
| 10/2021 | DNA Script | Series C | 0 |
| 9/2021 | TrialSpark | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
